ATOS
ATOSSA THERAPEUTICS, INC.
Next earnings Aug 10, 2026 · consensus $-1.05 EPS
$1.88
▲ +6.21%$1.88▼ -84.14%
over 1Y
L $1.75EODHDH $17.70
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.2%
1W+2.7%
1M-63.3%
3M-60.2%
YTD-80.1%
1Y-84.1%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Conservative balance sheet (liabilities/equity 0.21x); but revenue fell -95.6% YoY.
Revenue (FY2015) $1.76K · FY2015
ATOSSA THERAPEUTICS, INC. shows $1.76K in FY2015 revenue (-95.6% YoY), a -1977815.7% net margin, and -88.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$20.5M | -$27.7M | -$31.4M | -$27.6M | -$37.1M |
| Net income | -$20.6M | -$27.0M | -$30.1M | -$25.5M | -$34.8M |
| Diluted EPS | — | -$0.21 | -$0.24 | -$3.04 | -$4.04 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$25.1M
EV / EBITDA—
EV / Sales-14283.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-214.8%
FCF yield-184.0%
Quality & risk
ROIC (est.)-74.6%
Free cash flow-$29.8M
Total debt—
Net cash$41.3M
Altman Z-Score-7.71 distress
Piotroski F-Score2/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY-93.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-02-20). Worth a closer look.
Recent filings
all on EDGAR ↗424B5Filing2026-06-12open ↗8-KPeriod ending 2026-06-102026-06-11open ↗4Period ending 2026-05-122026-05-14open ↗4Period ending 2026-05-122026-05-14open ↗4Period ending 2026-05-122026-05-14open ↗4Period ending 2026-05-122026-05-14open ↗4Period ending 2026-05-122026-05-14open ↗4Period ending 2026-05-122026-05-14open ↗8-KPeriod ending 2026-05-082026-05-08open ↗10-QPeriod ending 2026-03-312026-05-08open ↗8-KPeriod ending 2026-05-072026-05-08open ↗8-KPeriod ending 2026-04-132026-04-16open ↗
Frequently asked
- Is ATOSSA THERAPEUTICS, INC. (ATOS) a buy?
- ATOS currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.21x); but revenue fell -95.6% YoY.
- What is ATOSSA THERAPEUTICS, INC.'s quality score?
- ATOS scores 31/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001488039, latest 10-Q filed 2026-05-08) · EODHD · as of 6/24/2026, 1:15:31 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.